<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Postgrad Med</journal-id><journal-id journal-id-type="iso-abbrev">J Postgrad Med</journal-id><journal-id journal-id-type="publisher-id">JPGM</journal-id><journal-title-group><journal-title>Journal of Postgraduate Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-3859</issn><issn pub-type="epub">0972-2823</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28272075</article-id><article-id pub-id-type="pmc">5664864</article-id><article-id pub-id-type="publisher-id">JPGM-63-215</article-id><article-id pub-id-type="doi">10.4103/0022-3859.201423</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The impact of topical Saint John's Wort (<italic>Hypericum perforatum</italic>) treatment on tissue tumor necrosis factor-alpha levels in plaque-type psoriasis: A pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mansouri</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mirafzal</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Najafizadeh</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Safaei-Naraghi</surname><given-names>Z</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib><contrib contrib-type="author"><name><surname>Salehi-Surmaghi</surname><given-names>MH</given-names></name><xref ref-type="aff" rid="aff5">4</xref></contrib><contrib contrib-type="author"><name><surname>Hashemian</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>1</label>Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran</aff><aff id="aff3"><label>2</label>Department of Pharmacology, Faculty of Pharmacy, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran</aff><aff id="aff4"><label>3</label>Department of Dermatopathology, Razi Skin Hospital, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff5"><label>4</label>Department of Pharmacognosy, Faculty of Pharmacy, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Farshad Hashemian, E-mail: <email xlink:href="hashemian.f@iaups.ac.ir">hashemian.f@iaups.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2017</year></pub-date><volume>63</volume><issue>4</issue><fpage>215</fpage><lpage>220</lpage><history><date date-type="received"><day>01</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>05</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Journal of Postgraduate Medicine</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Context:</title><p>Psoriasis is an inflammatory disorder, formed by inappropriate interaction of T lymphocytes with keratinocytes, and consequent eruption of immune responses. High concentrations of tumor necrosis factor-alpha (TNF&#x003b1;) are found in the skin lesions and plasma of patients with psoriasis. <italic>Hypericum perforatum</italic>, a phytomedicine that has both anti-inflammatory and antiproliferative properties, has been recently reported to be clinically helpful for improvement of psoriatic lesions.</p></sec><sec id="st2"><title>Aims:</title><p>The aim of the present study was to investigate the effects of topical <italic>H. perforatum</italic> on TNF&#x003b1; levels in psoriatic lesions for possible identification of the mechanism by which <italic>Hypericum</italic> reduces inflammation and modulates the disease in patients with plaque-type psoriasis.</p></sec><sec id="st3"><title>Settings and Design:</title><p>A double-blind, placebo-controlled, pilot study with intraindividual comparison was conducted on twenty patients with mild to moderate plaque-type psoriasis.</p></sec><sec id="st4"><title>Subjects and Methods:</title><p>TNF&#x003b1; levels in tissue samples were measured with immunohistochemistry method. Moreover, Psoriasis Area Severity Index (PASI) scores and histological and clinical changes were investigated after topical application of <italic>Hypericum</italic> extract.</p></sec><sec id="st5"><title>Statistical Analysis Used:</title><p>The Wilcoxon signed-rank test was used to evaluate the possible differences between the drug and placebo group.</p></sec><sec id="st6"><title>Results:</title><p>TNF&#x003b1; concentrations in dermis (<italic>p</italic>= 0.025), endothelial cells (<italic>p</italic>=0.033), and dendrite cells (<italic>p</italic>=0.014) were significantly reduced in lesions treated with drug and the reduction observed in epidermis was superior to placebo (<italic>p</italic>=0.046). Results of PASI scores showed that erythema, scaling, and thickness were significantly lower where the ointment had been applied compared to application of placebo (<italic>p</italic>=0.014, <italic>p</italic>=0.004, <italic>p</italic>=0.003, respectively). Moreover, significant improvement in clinical and histological features of treated lesions in comparison with untreated lesions was observed (<italic>p</italic> &#x0003c; 0.05).</p></sec><sec id="st7"><title>Conclusions:</title><p><italic>H. perforatum</italic> ointment can help decrease PASI scores and TNF&#x003b1; levels in psoriatic tissue. Its efficacy is probably related to its effect on lowering cytokines including TNF&#x003b1;.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd><italic>Hypericum perforatum</italic></kwd><kwd>plaque-type psoriasis</kwd><kwd>Psoriasis Area Severity Index scores</kwd><kwd>tumor necrosis factor-alpha</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Psoriasis is a chronic, multisystem inflammatory disorder which affects approximately 2%&#x02013;4% of people in the United States.[<xref rid="ref1" ref-type="bibr">1</xref>] Its prevalence has been reported to vary according to age, ethnicity, and geographic regions.[<xref rid="ref2" ref-type="bibr">2</xref>] For instance, its prevalence has been estimated to be 0.3%&#x02013;1.2% in Japan, 0.4% in China, and 4%&#x02013;5.5% in Malaysia.[<xref rid="ref3" ref-type="bibr">3</xref>] Psoriasis has a considerable effect on patients&#x02019; quality of life[<xref rid="ref4" ref-type="bibr">4</xref>] and imposes high economic impact on country's health-care system.[<xref rid="ref1" ref-type="bibr">1</xref>] Its pathogenesis has not been fully understood; however, recent studies have shown that defects in epidermal barrier-related genes are involved.[<xref rid="ref5" ref-type="bibr">5</xref>] Psoriasis is also approached as a hyperplasia in epidermis[<xref rid="ref6" ref-type="bibr">6</xref>] which is clinically categorized as a papulosquamous skin disorder.[<xref rid="ref7" ref-type="bibr">7</xref>] However, in plaque-type psoriasis, erythematous plaques usually covered by silver, flaking scales are recognized.[<xref rid="ref8" ref-type="bibr">8</xref>] Tumor necrosis factor-alpha (TNF&#x003b1;) is known to directly contribute to the characteristic plaque surmounted by silvery scales through induction of keratinocyte proliferation and prevention of keratinocyte apoptosis by increasing vasoactive intestinal peptide receptor and plasminogen activator inhibitor type 2, respectively.[<xref rid="ref9" ref-type="bibr">9</xref>] Moreover, upregulation of vascular endothelial growth factor and intercellular adhesion molecule-1/vascular cell adhesion molecule-1 is done by TNF&#x003b1; which in return promotes angiogenesis and microvascular permeability and targeting of lymphocytes to the inflammatory lesions, respectively.[<xref rid="ref10" ref-type="bibr">10</xref>] In addition, TNF&#x003b1; stimulates lymphocyte migration and increases expression of many proinflammatory cytokines including CCL27 (a skin-specific memory T-cell attractant) and nuclear factor kappa B (a ubiquitous transcription factor) which leads to the expression of many gene products that mediate inflammatory responses.[<xref rid="ref11" ref-type="bibr">11</xref>]</p><p>The most appropriate treatment for patients with mild to moderate psoriasis is known to be topical therapy.[<xref rid="ref12" ref-type="bibr">12</xref>] Mild to moderate psoriasis is defined as the Psoriasis Area Severity Index (PASI) score &#x02264;10 in the present study. Topical immunomodulators are also known to be an emerging therapy for psoriasis.[<xref rid="ref13" ref-type="bibr">13</xref>] Systemic and phototherapy are usually reserved for treatment of moderate to severe cases.[<xref rid="ref14" ref-type="bibr">14</xref>] Hyperforin, one of the chief active ingredients of <italic>Hypericum</italic>'s extract, is reported to have wound healing,[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>] anti-inflammatory,[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref>] and antibacterial properties.[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>]</p><p>It has been shown that <italic>Hypericum perforatum</italic> can be effective in patients with mild to moderate psoriasis by modulating the immune system through regulation of CD8-mediated cytotoxicity and inhibition of TNF&#x003b1;-induced apoptosis <italic>in vitro</italic>.[<xref rid="ref15" ref-type="bibr">15</xref>] However, further larger studies are needed to arrive at more conclusive results.[<xref rid="ref23" ref-type="bibr">23</xref>] Thus, the aim of this study was to investigate the effects of topical <italic>Hypericum</italic> on TNF&#x003b1; levels in psoriatic lesion in comparison with placebo in patients with plaque-type psoriasis.</p></sec><sec sec-type="methods" id="sec1-2"><title>Subjects and Methods</title><p>Twenty patients were enrolled in the present double-blind, placebo-controlled, and intraindividual comparison pilot study. Inclusion criteria were patients with the age between 18 and 55 years old; diagnosis of mild to moderate plaque-type psoriasis on both sides of the body; and not being under medical treatment for the past 2 months. Exclusion criteria were pregnancy, lactation, suffering from a major illness (such as cardiovascular disease, acute renal or liver disease, cancer, or active malignancy), and not having plaque psoriasis on both sides of the body. The study was approved by the Ethics Committee of Islamic Azad University, Pharmaceutical Sciences Branch (Number= 7173) and all patients participated in the study were informed of the study procedure and signed written consent forms. Moreover, the study was registered in Iranian Clinical Trials Center (IRCT) (Registration Number: IRCT201503173106N24). Due to the design as a pilot study and obligation of Ethics Committee (since the study needed tissue sampling from the patients), the sample size was limited to 20. However, 8 patients refused to give tissue samples at the point of sampling. Thus, 12 patients remained in the study.</p><p>After scoring clinical features and taking one biopsy from a psoriatic lesion of each patient, they received both <italic>H. perforatum</italic> ointment and placebo (vehicle), one applied randomly to the right and the other to the left side of the body twice daily for duration of 4 weeks. After that, along with clinical investigations, two punch biopsies (6 mm) each from lesions of the right and left side (the preferred symmetrically) were taken to examine the difference between drug and placebo group before and after the treatment.</p><p>Patients&#x02019; outcomes were evaluated according to PASI scores which were obtained at baseline and the end of 4 weeks period, by a senior dermatologist. Moreover, immunohistochemical (IHC) staining of the tissues was done to compare TNF&#x003b1; levels in the psoriatic tissues. Any possible side effects were recorded. PASI score (according to erythema, thickness, and scaling) was determined before and after the treatment, which were based on a 0&#x02013;3 grade system, where 0 indicated an absence of the symptom, and 3 showed maximum severity. For the IHC study, paraffinized sections (5 &#x003bc;m) of the skin tissue was stained using a mouse anti-human TNF&#x003b1; (28401.111) monoclonal antibody (Santa Cruz Biotechnology Company) as the primary antibody and a goat anti-mouse IgG detected with envision as the secondary antibody. The intensity of TNF&#x003b1; IHC staining was measured using NIS Elements Software (Nikon Instruments Inc., New York, USA).</p><p>The formulated ointment was prepared from an extract of <italic>H. perforatum</italic> L (5% wt/wt), vaseline (84% wt/wt), propylene glycol (10% wt/wt), and avicel (1% wt/wt). The <italic>Hypericum</italic> extract which was extracted from the <italic>Hypericum</italic> plant was provided by Poursina Co. (Tehran, Iran). The vehicle was the same in the placebo and the active ointments contained the same percentages of propylene glycol, vaseline, and avicel. The formulations were packed in airtight bottles and went through stability tests. They were stored at 0&#x000b0;C, 30&#x000b0;C, and 45&#x000b0;C at different predetermined intervals (i.e., 30, 60 and 90 days), and their appearance, spreadability, texture, and phase separation were studied. Physical changes to color, odor, smoothness, and phase separation were observed visually during the study.</p><p>Two types of bottles were prepared, one filled with the drug formulation and the other with the same amount of placebo. Thus, drug and placebo were exactly identical in terms of their appearance and could not be identified neither by the clinician nor the patient. Moreover, the bottles were coded by a third party who wrote down the codes in a table, and the third party himself decoded the bottles at the end of the study.</p><p>Obtained data were analyzed by SPSS software (version 18.0, SPSS Inc, Chicago, Illinois). The Wilcoxon signed-rank test was used to evaluate the possible differences between the drug and placebo group. <italic>P</italic> &#x0003c; 0.05 were assumed statistically significant.</p></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>Three of the patients were male, and eight patients were females. The mean age of the patients was calculated to be 41.25 &#x000b1; 14.24. Two patients had the history of only skin involvement; whereas six patients had history of both skin and joint involvement. Moreover, four patients had history of both skin and nail involvement, and two patients had the history of skin, nail, and joint involvement. Mean duration of therapy before enrolling in the present study was calculated to be 1.41 years. Moreover, it should be noted that none of the patients were on biologics before the study. In IHC-stained samples, TNF&#x003b1; concentration in epidermis, endothelial cells, and dendrite cells was significantly reduced in lesions treated with drug (<italic>p</italic>=0.025, <italic>p</italic>=0.033, <italic>p</italic>=0.014, respectively) and the reduction in TNF&#x003b1; concentration was reported to be superior to placebo in epidermis tissue [<italic>p</italic>=0.046, <xref ref-type="table" rid="T1">Table 1</xref>]. Images showing clinical photos before and after the treatment are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Tissue tumor necrosis factor-alpha levels before and after treatment (pg/ml)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">TNF&#x003b1; level in parakeratosis tissue</th><th align="center" rowspan="1" colspan="1">TNF&#x003b1; level in epidermis</th><th align="center" rowspan="1" colspan="1">TNF&#x003b1; level in basal layer</th><th align="center" rowspan="1" colspan="1">TNF&#x003b1; level in endothelial tissue</th><th align="center" rowspan="1" colspan="1">TNF&#x003b1; level in dendritic cells</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean concentration before treatment</td><td align="center" rowspan="1" colspan="1">1.41</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">1.58</td><td align="center" rowspan="1" colspan="1">1.50</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean concentration after treatment with drug</td><td align="center" rowspan="1" colspan="1">0.83</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean concentration after treatment with placebo</td><td align="center" rowspan="1" colspan="1">1.08</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">1.41</td><td align="center" rowspan="1" colspan="1">1.41</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference in mean concentration after treatment with drug</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">0.42</td><td align="center" rowspan="1" colspan="1">0.66</td><td align="center" rowspan="1" colspan="1">0.50</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference in mean concentration after treatment with placebo</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Before and after treatment with drug (<italic>p</italic>)</td><td align="center" rowspan="1" colspan="1">0.35</td><td align="center" rowspan="1" colspan="1">0.025</td><td align="center" rowspan="1" colspan="1">0.212</td><td align="center" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Before and after treatment with placebo (<italic>p</italic>)</td><td align="center" rowspan="1" colspan="1">0.157</td><td align="center" rowspan="1" colspan="1">0.564</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.564</td><td align="center" rowspan="1" colspan="1">0.180</td></tr><tr><td align="left" rowspan="1" colspan="1">Difference between drug and placebo group (<italic>p</italic>)</td><td align="center" rowspan="1" colspan="1">0.083</td><td align="center" rowspan="1" colspan="1">0.046</td><td align="center" rowspan="1" colspan="1">0.336</td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">0.083</td></tr></tbody></table><table-wrap-foot><fn><p>TNF&#x003b1;: Tumor necrosis factor-alpha</p></fn></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Clinical images before and after the treatment. (a) Left foot before treatment. (b) Left foot after treatment with drug. (c) Right foot before treatment. (d) Right foot after treatment with base ointment</p></caption><graphic xlink:href="JPGM-63-215-g001"/></fig><p>According to the clinical investigations, disease severity was shown to be significantly reduced by 1-month application of the drug. However, reduction of thickness, scaling, and pruritus scores was more significant. Thickness and scaling scores were reduced by the placebo ointment as well, however, when compared with the drug ointment, reduction observed by application of the drug ointment was shown to be superior to the placebo ointment [<xref ref-type="table" rid="T2">Table 2</xref>]. Reduction of erythema, scaling, thickness, and pruritus scores after application of drug and placebo are compared and shown in <xref ref-type="table" rid="T2">Table 2</xref>. Moreover, images showing pathologic results with H and E and IHC staining are shown in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><italic>P</italic> values obtained from Wilcoxon tests to compare reduction of Psoriasis Area Severity Index scores with drug and placebo before and after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">After treatment with drug</th><th align="center" rowspan="1" colspan="1">After treatment with placebo</th><th align="center" rowspan="1" colspan="1">Comparison of placebo and formulated ointment after treatment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Erythema score</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">0.414</td><td align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Scaling score</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Thickness score</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus score</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.096</td><td align="center" rowspan="1" colspan="1">0.008</td></tr></tbody></table></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>Pathological images before and after the treatment. (a) Foot tissue before treatment. (b) Left foot tissue after treatment with drug. (c) Right foot tissue after treatment with base ointment (a-c: H and E, &#x000d7;10). (d) Immunohistochemical staining before treatment. (e) Immunohistochemical staining after treatment with drug. (f) Immunohistochemical staining after treatment with base ointment (d-f: AEC and TMB [HRP], &#x000d7;40)</p></caption><graphic xlink:href="JPGM-63-215-g002"/></fig><p>All the histological features that show the active stage of the disease including spongiosis, acanthosis, parakeratosis, thinning of suprapapillary plates, Munro microabscesses, and spongiform pustules of Kogoj were significantly reduced in tissue samples of lesions treated with drug ointment (<italic>p</italic> &#x0003c; 0.05) while acanthosis, hypogranulosis, and suprapapillary thinning were more significantly reduced (<italic>p</italic> = 0.003, <italic>p</italic> = 0.008, <italic>p</italic> = 0.007), respectively. Except for parakeratosis and spongiosis which did not change with placebo treatment, other histological features were improved with placebo treatment as well (<italic>p</italic> &#x0003c; 0.05). Reduction reported in spongiosis, parakeratosis, and suprapapillary thinning in drug-treated tissues were significantly superior to placebo (<italic>p</italic> &#x0003c; 0.05). Diluted vessels and edema in papillary dermis and leukocyte infiltration did not change significantly during 1-month topical treatment but fibrosis which shows the entrance of lesions into remission stage was significantly increased in tissues treated with the drug ointment [<italic>p</italic> &#x0003c; 0.05, <xref ref-type="table" rid="T3">Table 3</xref>]. Different pathological features including parakeratosis, acanthosis, and fibrosis are compared after drug and placebo application and are shown in <xref ref-type="table" rid="T3">Table 3</xref>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Pathological features before and after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Before and after treatment with drug (<italic>p</italic>)</th><th align="center" rowspan="1" colspan="1">Before and after treatment with placebo (<italic>p</italic>)</th><th align="center" rowspan="1" colspan="1">Comparison of placebo and formulated ointment (<italic>p</italic>) after treatment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Parakeratosis</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">0.132</td><td align="center" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Acanthosis</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" rowspan="1" colspan="1">Spongiosis</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">0.361</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypogranulosis</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">Thinning of suprapapillary plates</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Munro microabscesses</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.317</td></tr><tr><td align="left" rowspan="1" colspan="1">Spongiform pustules of Kogoj</td><td align="center" rowspan="1" colspan="1">0.023</td><td align="center" rowspan="1" colspan="1">0.035</td><td align="center" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" rowspan="1" colspan="1">Edema in papillary dermis</td><td align="center" rowspan="1" colspan="1">0.180</td><td align="center" rowspan="1" colspan="1">0.100</td><td align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" rowspan="1" colspan="1">Dilated vessels</td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">0.257</td><td align="center" rowspan="1" colspan="1">0.480</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocyte</td><td align="center" rowspan="1" colspan="1">0.206</td><td align="center" rowspan="1" colspan="1">0.025</td><td align="center" rowspan="1" colspan="1">0.650</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophil</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" rowspan="1" colspan="1">Eosinophils</td><td align="center" rowspan="1" colspan="1">0.100</td><td align="center" rowspan="1" colspan="1">0.317</td><td align="center" rowspan="1" colspan="1">0.317</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma cells</td><td align="center" rowspan="1" colspan="1">0.083</td><td align="center" rowspan="1" colspan="1">0.564</td><td align="center" rowspan="1" colspan="1">0.157</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibroblast</td><td align="center" rowspan="1" colspan="1">0.257</td><td align="center" rowspan="1" colspan="1">0.033</td><td align="center" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrosis</td><td align="center" rowspan="1" colspan="1">0.046</td><td align="center" rowspan="1" colspan="1">0.317</td><td align="center" rowspan="1" colspan="1">0.180</td></tr></tbody></table></table-wrap><p>Both drug and placebo ointment were well tolerated by the patients, and there was no report of allergic reactions and side effects. One patient had recurrence of the lesions.</p><p>Sites of involvement were hands and feet, and there was no difference in the resolution of plaques depending on the site of involvement.</p></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>It has been shown that topical preparations of <italic>H. perforatum</italic> can be effective in wound healing, atopic dermatitis, and mild to moderate psoriasis. However, further larger studies are needed to arrive at more conclusive results.[<xref rid="ref15" ref-type="bibr">15</xref>] Thus, the present study was designed to investigate the effects of <italic>H. perforatum</italic>'s extract on TNF&#x003b1; levels in psoriatic tissue for possible identification of the mechanism by which <italic>Hypericum</italic>, modulates the disease, and decreases inflammation.</p><p>Najafizadeh <italic>et al</italic>. investigated the clinical effects of topical <italic>H. perforatum</italic> in plaque-type psoriasis. According to the results, all factors of PASI scores including erythema, scaling, and thickness were decreased significantly where the formulated ointment was applied. However, conduction of further studies was suggested.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>The results of the present study were in consistence with the results of Najafizadeh <italic>et al</italic>.'s study. In other words, it was shown that <italic>Hypericum</italic> ointment could decrease erythema, scaling, and thickness in patients with mild to moderate plaque-type psoriasis. Superior reduction of thickness and scaling of the lesions with drug application can be the result of reduction of epidermal hyperproliferation and improvement of keratinocytes&#x02019; differentiation and natural formation of epidermal layers. Naftodiantrones in <italic>Hypericum</italic> extract such as hypericin and pseudohypericin can inhibit C-protein kinase; thus, be effective in reduction of proliferation rate of epidermal cells.[<xref rid="ref24" ref-type="bibr">24</xref>] Hyperforin can also reduce keratinocytes&#x02019; proliferation by increasing apoptotic cell death.[<xref rid="ref25" ref-type="bibr">25</xref>]</p><p>Moderate reduction in the area of involvement and erythema in lesions treated with drug can be the result of decrease in permeability and dilution of capillary vessels and reduction of edema in dermis of the lesions. Quercetin and amentoflavone <italic>Hypericum</italic> extract inhibit lipid inflammatory mediators production (which increase vascular permeability) and reduce TNF&#x003b1; and interleukin (IL)-6 which can lead to reduction of edema and inflammation.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>] Reduction in neutrophils by the application of <italic>Hypericum</italic> could be due to the effects of quercetin, hyperforin, or chlorogenic acid on the inhibition of neutrophils&#x02019; chemoattraction to skin, through reduction of adhesion molecules or leukotrienes or both.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>] Reduction of TNF&#x003b1; concentrations in tissues treated with drug could be the result of inhibitory effects of quercetin and amentoflavone on production of TNF&#x003b1; or the result of inhibitory effects of hyperforin on activation of T lymphocytes, and therefore, suppression of initiating process.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref28" ref-type="bibr">28</xref>] Studies by Tobin and Kirby on effects of TNF&#x003b1; inhibitors on treatment of psoriasis support this result.[<xref rid="ref29" ref-type="bibr">29</xref>]</p><p>Xiuying <italic>et al</italic>. studied the effects of <italic>H. perforatum</italic> on treatment of flu infection in mouse. According to the results, <italic>Hypericum</italic>'s extract was reported to decrease TNF&#x003b1; and IL-6 concentrations and increase interferon &#x003b3; and IL-10 levels in mice lungs and serum.[<xref rid="ref30" ref-type="bibr">30</xref>] In another study investigating the effects of <italic>Hypericum</italic>'s extract's on reduction of lung injury in mouse, the extract was reported to decrease TNF&#x003b1; and IL-1&#x003b2;.[<xref rid="ref31" ref-type="bibr">31</xref>] Moreover, in another study, the effects of <italic>H. perforatum</italic>'s extract on irritable bowel syndrome were evaluated in rats. According to the results, the extract decreased TNF&#x003b1; and inflammatory cells accumulation.[<xref rid="ref32" ref-type="bibr">32</xref>] However, studies by Canning <italic>et al</italic>. showed that <italic>Hypericum</italic> had probably no significant effect on cytokines levels in premenstrual syndrome in women.[<xref rid="ref33" ref-type="bibr">33</xref>]</p><p>It has been suggested that anti-inflammatory effects of <italic>H. perforatum</italic> components appear in higher concentrations than what is in the extract, except for pseudohypericin, and hyperforin whose effects appear at concentrations near to what's in the extract. However, there is a belief that all these components next to each other can synergistically exhibit a significant anti-inflammatory effect. Moreover, it has been suggested that four compounds, namely, pseudohypericin, quercetin, amentoflavone, and chlorogenic acid all together, while being purified out of extract, can reduce TNF&#x003b1; but while into extract cannot have such effect.[<xref rid="ref34" ref-type="bibr">34</xref>]</p></sec><sec sec-type="conclusion" id="sec1-5"><title>Conclusion</title><p><italic>H. perforatum</italic> ointment helps reduce PASI scores and TNF&#x003b1; levels in psoriatic tissue in patients with plaque-type psoriasis. Its efficacy is probably related to its effect on lowering cytokines including TNF&#x003b1;.</p><sec id="sec2-1"><title>Financial support and sponsorship</title><p>Financial support was provided by the Islamic Azad University, Pharmaceutical Sciences Branch, a nongovernmental nonprofit organization.</p></sec><sec id="sec2-2" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgment</title><p>We wish to thank Dr. Elnaz Roohi for her insightful comments in reviewing and editing the manuscript.</p></ack><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>R</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Ashcroft</surname><given-names>DM</given-names></name></person-group><article-title>Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) Project Team. Global epidemiology of psoriasis: A systematic review of incidence and prevalence</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">23014338</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name></person-group><article-title>Psoriasis: Epidemiology, clinical features, and quality of life</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><issue>Suppl 2</issue><fpage>ii18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15708928</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimmino</surname><given-names>MA</given-names></name></person-group><article-title>Epidemiology of psoriasis and psoriatic arthritis</article-title><source>Reumatismo</source><year>2007</year><volume>59</volume><issue>Suppl 1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17828354</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhosle</surname><given-names>MJ</given-names></name><name><surname>Kulkarni</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Balkrishnan</surname><given-names>R</given-names></name></person-group><article-title>Quality of life in patients with psoriasis</article-title><source>Health Qual Life Outcomes</source><year>2006</year><volume>4</volume><fpage>35</fpage><pub-id pub-id-type="pmid">16756666</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>S</given-names></name></person-group><article-title>Psoriasis as a barrier disease</article-title><source>Dermatol Sin</source><year>2015</year><volume>33</volume><fpage>64</fpage><lpage>9</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrijan</surname><given-names>L</given-names></name><name><surname>Lipozencic</surname><given-names>J</given-names></name><name><surname>Batinac</surname><given-names>T</given-names></name><name><surname>Lenkovic</surname><given-names>M</given-names></name><name><surname>Stanic-&#x0017d;gombic</surname><given-names>Z</given-names></name><name><surname>Greguric</surname><given-names>S</given-names></name></person-group><article-title>Psoriasis vulgaris &#x02013; An inflammatory skin disease and/or benign epidermal hyperplasia</article-title><source>Acta Dermatovenerol Croat</source><year>2011</year><volume>19</volume><fpage>117</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21703160</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>G</given-names></name><name><surname>Mignogna</surname><given-names>C</given-names></name></person-group><article-title>The histopathology of psoriasis</article-title><source>Reumatismo</source><year>2007</year><volume>59</volume><issue>Suppl 1</issue><fpage>46</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17828343</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>K</given-names></name><name><surname>Gulliver</surname><given-names>W</given-names></name><name><surname>Lynde</surname><given-names>C</given-names></name><name><surname>Poulin</surname><given-names>Y</given-names></name><name><surname>Ashkenas</surname><given-names>J</given-names></name></person-group><article-title>Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: Overview</article-title><source>J Cutan Med Surg</source><year>2011</year><volume>15</volume><fpage>210</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21781627</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>AB</given-names></name><name><surname>Masud</surname><given-names>S</given-names></name><name><surname>Ramamurthi</surname><given-names>R</given-names></name><name><surname>Abdulghani</surname><given-names>A</given-names></name><name><surname>Romano</surname><given-names>P</given-names></name><name><surname>Chaudhari</surname><given-names>U</given-names></name><etal/></person-group><article-title>Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris</article-title><source>J Am Acad Dermatol</source><year>2003</year><volume>48</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12522373</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>T</given-names></name><name><surname>Mullan</surname><given-names>R</given-names></name><name><surname>Golden-Mason</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Bresnihan</surname><given-names>B</given-names></name><name><surname>Fitzgerald</surname><given-names>O</given-names></name><etal/></person-group><article-title>Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>54</volume><fpage>1003</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16713454</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banno</surname><given-names>T</given-names></name><name><surname>Gazel</surname><given-names>A</given-names></name><name><surname>Blumenberg</surname><given-names>M</given-names></name></person-group><article-title>Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>32633</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15145954</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name></person-group><article-title>In touch with psoriasis: Topical treatments and current guidelines</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><volume>25</volume><issue>Suppl 4</issue><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21507077</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khandpur</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>VK</given-names></name><name><surname>Sumanth</surname><given-names>K</given-names></name></person-group><article-title>Topical immunomodulators in dermatology</article-title><source>J Postgrad Med</source><year>2004</year><volume>50</volume><fpage>131</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15235214</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>MW</given-names></name><name><surname>Weinstein</surname><given-names>GD</given-names></name></person-group><article-title>Treatment of psoriasis</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>581</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7838193</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000f6;lfle</surname><given-names>U</given-names></name><name><surname>Seelinger</surname><given-names>G</given-names></name><name><surname>Schempp</surname><given-names>CM</given-names></name></person-group><article-title>Topical application of St. John's wort (<italic>Hypericum perforatum</italic>)</article-title><source>Planta Med</source><year>2014</year><volume>80</volume><fpage>109</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">24214835</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>S</given-names></name><name><surname>Khadivzadeh</surname><given-names>T</given-names></name><name><surname>Emami</surname><given-names>A</given-names></name><name><surname>Moosavi</surname><given-names>NS</given-names></name><name><surname>Tafaghodi</surname><given-names>M</given-names></name><name><surname>Behnam</surname><given-names>HR</given-names></name></person-group><article-title>The effect of <italic>Hypericum perforatum</italic> on the wound healing and scar of cesarean</article-title><source>J Altern Complement Med</source><year>2010</year><volume>16</volume><fpage>113</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20064022</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozt&#x000fc;rk</surname><given-names>N</given-names></name><name><surname>Korkmaz</surname><given-names>S</given-names></name><name><surname>Ozt&#x000fc;rk</surname><given-names>Y</given-names></name></person-group><article-title>Wound-healing activity of St. John's wort (<italic>Hypericum perforatum</italic> L.) on chicken embryonic fibroblasts</article-title><source>J Ethnopharmacol</source><year>2007</year><volume>111</volume><fpage>33</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17156955</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotblatt</surname><given-names>MD</given-names></name><name><surname>Khadivzadeh</surname><given-names>T</given-names></name></person-group><article-title>Topical <italic>Hypericum perforatum</italic> (St. John's wort) for wound healing and scar formation</article-title><source>Focus Altern Complement Ther</source><year>2010</year><volume>15</volume><fpage>234</fpage><lpage>6</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>D</given-names></name><name><surname>Z&#x000fc;ndorf</surname><given-names>I</given-names></name><name><surname>Dingermann</surname><given-names>T</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>WE</given-names></name><name><surname>Steinhilber</surname><given-names>D</given-names></name><name><surname>Werz</surname><given-names>O</given-names></name></person-group><article-title>Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase</article-title><source>Biochem Pharmacol</source><year>2002</year><volume>64</volume><fpage>1767</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12445866</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosa</surname><given-names>S</given-names></name><name><surname>Pace</surname><given-names>R</given-names></name><name><surname>Bornancin</surname><given-names>A</given-names></name><name><surname>Morazzoni</surname><given-names>P</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Tubaro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Topical anti-inflammatory activity of extracts and compounds from <italic>Hypericum perforatum</italic> L</article-title><source>J Pharm Pharmacol</source><year>2007</year><volume>59</volume><fpage>703</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17524236</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saddiqe</surname><given-names>Z</given-names></name><name><surname>Naeem</surname><given-names>I</given-names></name><name><surname>Maimoona</surname><given-names>A</given-names></name></person-group><article-title>A review of the antibacterial activity of <italic>Hypericum perforatum</italic> L</article-title><source>J Ethnopharmacol</source><year>2010</year><volume>131</volume><fpage>511</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20659547</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schempp</surname><given-names>CM</given-names></name><name><surname>Pelz</surname><given-names>K</given-names></name><name><surname>Wittmer</surname><given-names>A</given-names></name><name><surname>Sch&#x000f6;pf</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>JC</given-names></name></person-group><article-title>Antibacterial activity of hyperforin from St. John's wort, against multiresistant <italic>Staphylococcus aureus</italic> and gram-positive bacteria</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>2129</fpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najafizadeh</surname><given-names>P</given-names></name><name><surname>Hashemian</surname><given-names>F</given-names></name><name><surname>Mansouri</surname><given-names>P</given-names></name><name><surname>Farshi</surname><given-names>S</given-names></name><name><surname>Surmaghi</surname><given-names>MS</given-names></name><name><surname>Chalangari</surname><given-names>R</given-names></name></person-group><article-title>The evaluation of the clinical effect of topical St. Johns wort (<italic>Hypericum perforatum</italic> L.) in plaque type psoriasis vulgaris: A pilot study</article-title><source>Australas J Dermatol</source><year>2012</year><volume>53</volume><fpage>131</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22571563</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>I</given-names></name><name><surname>Nakanishi</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>E</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Tamaoki</surname><given-names>T</given-names></name></person-group><article-title>Hypericin and pseudohypericin specifically inhibit protein kinase C: Possible relation to their antiretroviral activity</article-title><source>Biochem Biophys Res Commun</source><year>1989</year><volume>165</volume><fpage>1207</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">2558652</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaher</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Bombarda</surname><given-names>I</given-names></name><name><surname>Merhi</surname><given-names>F</given-names></name><name><surname>Bauvois</surname><given-names>B</given-names></name><name><surname>Billard</surname><given-names>C</given-names></name></person-group><article-title>Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa</article-title><source>Int J Oncol</source><year>2012</year><volume>40</volume><fpage>269</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">21947285</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askari</surname><given-names>G</given-names></name><name><surname>Ghiasvand</surname><given-names>R</given-names></name><name><surname>Feizi</surname><given-names>A</given-names></name><name><surname>Ghanadian</surname><given-names>SM</given-names></name><name><surname>Karimian</surname><given-names>J</given-names></name></person-group><article-title>The effect of quercetin supplementation on selected markers of inflammation and oxidative stress</article-title><source>J Res Med Sci</source><year>2012</year><volume>17</volume><fpage>637</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23798923</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azza</surname><given-names>EM</given-names></name><name><surname>Yieldez</surname><given-names>B</given-names></name><name><surname>Mahmoud</surname><given-names>K</given-names></name><name><surname>Abdullatif</surname><given-names>M</given-names></name></person-group><article-title>Chlorogenic acid as potential anti- inflammatory analgesic agent: An investigation of the possible role of nitrogen-based radicals in rats</article-title><source>Int J Pharmacol Toxicol Sci</source><year>2011</year><volume>1</volume><fpage>24</fpage><lpage>33</lpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meinke</surname><given-names>MC</given-names></name><name><surname>Schanzer</surname><given-names>S</given-names></name><name><surname>Haag</surname><given-names>SF</given-names></name><name><surname>Casetti</surname><given-names>F</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>ML</given-names></name><name><surname>W&#x000f6;lfle</surname><given-names>U</given-names></name><etal/></person-group><article-title><italic>In vivo</italic> photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity <italic>in vitro</italic> and <italic>ex vivo</italic></article-title><source>Eur J Pharm Biopharm</source><year>2012</year><volume>81</volume><fpage>346</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22430217</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>AM</given-names></name><name><surname>Kirby</surname><given-names>B</given-names></name></person-group><article-title>TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis</article-title><source>BioDrugs</source><year>2005</year><volume>19</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15691217</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiuying</surname><given-names>P</given-names></name><name><surname>Jianping</surname><given-names>L</given-names></name><name><surname>Ruofeng</surname><given-names>S</given-names></name><name><surname>Liye</surname><given-names>Z</given-names></name><name><surname>Xuehong</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name></person-group><article-title>Therapeutic efficacy of <italic>Hypericum perforatum</italic> L. extract for mice infected with an influenza a virus</article-title><source>Can J Physiol Pharmacol</source><year>2012</year><volume>90</volume><fpage>123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">22260349</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menegazzi</surname><given-names>M</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Mui&#x000e0;</surname><given-names>C</given-names></name><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Crisafulli</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic>Hypericum perforatum</italic> attenuates the development of carrageenan-induced lung injury in mice</article-title><source>Free Radic Biol Med</source><year>2006</year><volume>40</volume><fpage>740</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16520227</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffari</surname><given-names>S</given-names></name><name><surname>Esmaily</surname><given-names>H</given-names></name><name><surname>Rahimi</surname><given-names>R</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Sanei</surname><given-names>Y</given-names></name><name><surname>Asadi-Shahmirzadi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of <italic>Hypericum perforatum</italic> extract on rat irritable bowel syndrome</article-title><source>Pharmacogn Mag</source><year>2011</year><volume>7</volume><fpage>213</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">21969792</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canning</surname><given-names>S</given-names></name><name><surname>Waterman</surname><given-names>M</given-names></name><name><surname>Orsi</surname><given-names>N</given-names></name><name><surname>Ayres</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>N</given-names></name><name><surname>Dye</surname><given-names>L</given-names></name></person-group><article-title>The efficacy of <italic>Hypericum perforatum</italic> (St. John's wort) for the treatment of premenstrual syndrome: A randomized, double-blind, placebo-controlled trial</article-title><source>CNS Drugs</source><year>2010</year><volume>24</volume><fpage>207</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">20155996</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>KD</given-names></name></person-group><source>Elucidation of Anti-inflammatory Constituents in Hypericum perforatum Extracts and Delineation of Mechanisms of Anti-inflammatory Activity in RAW 264.7 Mouse Macrophages</source><date-in-citation>Last accessed on 2015 Aug 15</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.lib.dr.iastate.edu/cgi/viewcontent.cgi?article=16773andcontext=rtd">http://www.lib.dr.iastate.edu/cgi/viewcontent.cgi?article=16773 and context=rtd</uri></comment></element-citation></ref></ref-list></back></article>